Cell Isolation and Organ Function Core
细胞分离和器官功能核心
基本信息
- 批准号:10437830
- 负责人:
- 金额:$ 32.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-20 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Respiratory Distress SyndromeAtherosclerosisBiologyBlood VesselsBronchopulmonary DysplasiaBusinessesCardiac MyocytesCardiac developmentCardiopulmonaryCell SeparationCell physiologyCellsCenters of Research ExcellenceCongenital Heart DefectsConsultationsCultured CellsDataDevelopmentDisease ProgressionEndothelial CellsEndotheliumEnsureExperimental DesignsFibroblastsFunctional disorderGoalsHeartHeart DiseasesImageImage AnalysisInjuryInterruptionLasersLeadLungLung diseasesMeasurementMutationOrganPathogenesisPhasePhenotypeProceduresProcessProductivityPulmonary HypertensionReproducibilityResearchResearch PersonnelResearch Project GrantsResourcesRhode IslandServicesStructureSystemTechnologyTissuesTranslatingVascular DiseasesVascular remodelingangiogenesiscell typegenetic manipulationheart functionidiopathic pulmonary fibrosisin vivoinjury and repairinstrumentationmorphometrynovelpulmonary functionrepairedresponseresponse to injuryskillstooltranscription factorvascular injury
项目摘要
The central goals of the CardioPulmonary Vascular Biology (CPVB) Center for Biomedical Research
Excellence (COBRE) are to understand basic mechanisms of vascular disease pathogenesis and to translate
these findings into treatments for heart and lung diseases. Vascular injury, repair, and remodeling are critical
to the pathogenesis of the conditions studied in Phase II projects--bronchopulmonary dysplasia (BPD),
atherosclerosis, idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and acute respiratory distress
syndrome (ARDS). Cardiac development and remodeling in response to injury similarly include both adaptive
and maladaptive responses. Dysfunction of angiogenesis, the reparative response of the endothelium to injury,
and aberrant vascular remodeling have been proposed to occur in ARDS, BPD, IPF and other heart and lung
conditions. In addition, some congenital heart defects result from mutations in transcription factors that
regulate cardiomyocyte and endothelial cell (EC) function in development. Thus, an increased understanding
of the mechanisms regulating the adaptation of the vasculature to injury and repair may lead to unique
approaches to interrupt disease progression or to promote or enhance cardiopulmonary vascular repair.
During Phase I the Cell/Organ Core developed centralized systems for cell isolations and organ function
measurements and provided reproducible and accurate data for COBRE Projects. Additional services
underway to enhance the Cell/Organ Core capabilities for the vascular biologists in Rhode Island and Phase II
investigators are expansion of i) type of cell isolations; ii) immunohistochemical analyses; iii) EC function of
primary isolates; iv) laser Doppler imaging; and v) in vivo angiogenesis. The Core will offer consultation on
experimental design, provide cutting edge technological approaches, generate and analyze data, and serve as
a resource for CPVB COBRE investigators and others in Rhode Island. The Core will also develop a business
plan for financial stability of existing services and identify novel business or collaborative opportunities to
ensure sustainability of the CPVB core. The overall goal of the Cell/Organ Core is to facilitate the scientific
objectives and technical repertoire of the Project and Pilot Investigators by the following specific aims. (1)
Enhance the productivity of CPVB COBRE research projects by offering reproducible, economical, and high
quality i) cell isolation, propagation, phenotypic characterization and functional assessment ii) assessment of
heart, lung, vessel structure and function and angiogenesis, and (iii) transient gene manipulation in vivo. (2)
Acquire, establish, and disseminate technologies and instrumentation to provide state of the art research tools
for vascular biology research in Rhode Island. (3) Establish processes and procedures that support the
sustainability of the Cell/Organ Core. The CPVB COBRE Cell/Organ Core will support vascular biology
research, including new investigators, projects, technical approaches and ideas that enhance the impact of
research in Rhode Island.
肺血管生物学(CPVB)生物医学研究中心的中心目标
卓越(COBRE)的目的是了解血管疾病发病机制的基本机制,
将这些发现用于治疗心脏和肺部疾病。血管损伤、修复和重塑至关重要
II期项目中研究的疾病的发病机制-支气管肺发育不良(BPD),
动脉粥样硬化、特发性肺纤维化(IPF)、肺动脉高压和急性呼吸窘迫
综合征(ARDS)。心脏发育和重塑对损伤的反应类似地包括适应性和非适应性。
和适应不良的反应血管生成功能障碍,内皮对损伤的修复反应,
并且已经提出在ARDS、BPD、IPF和其他心脏和肺疾病中发生异常血管重构。
条件此外,一些先天性心脏缺陷是由转录因子突变引起的,
在发育中调节心肌细胞和内皮细胞(EC)的功能。因此,
调节血管系统对损伤和修复的适应性的机制可能导致独特的
中断疾病进展或促进或增强心肺血管修复的方法。
在第一阶段,细胞/器官核心开发了用于细胞分离和器官功能的集中系统
测量并为COBRE项目提供可重复和准确的数据。附加服务
正在进行中的细胞/器官核心的能力,为血管生物学家在罗得岛和第二阶段
研究人员正在扩大i)细胞分离的类型; ii)免疫组织化学分析; iii)EC功能,
原代分离物; iv)激光多普勒成像;和v)体内血管生成。核心将提供咨询,
实验设计,提供尖端的技术方法,生成和分析数据,并作为
为CPVB COBRE调查员和其他在罗得岛的人提供的资源。核心还将开发一项业务
计划现有服务的财务稳定性,并确定新的业务或合作机会,
确保CPVB核心的可持续性。细胞/器官核心的总体目标是促进科学
项目和试点研究人员的目标和技术曲目,具体目标如下。(一)
通过提供可重复的、经济的和高效率的产品,提高CPVB COBRE研究项目的生产力。
质量i)细胞分离、增殖、表型表征和功能评估ii)
心脏、肺、血管结构和功能以及血管生成,以及(iii)体内瞬时基因操作。(二更)
获取,建立和传播技术和仪器,以提供最先进的研究工具
在罗得岛进行血管生物学研究。(3)建立支持以下方面的流程和程序:
细胞/器官核心的可持续性。CPVB COBRE细胞/器官核心将支持血管生物学
研究,包括新的调查人员,项目,技术方法和想法,以加强影响,
在罗得岛做研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth O Harrington其他文献
Elizabeth O Harrington的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth O Harrington', 18)}}的其他基金
“Phenotyping Heart Failure with Preserved Ejection Fraction Using Non- Invasive Biomarkers
使用非侵入性生物标志物通过保留射血分数对心力衰竭进行表型分析
- 批准号:
10624557 - 财政年份:2022
- 资助金额:
$ 32.49万 - 项目类别:
Uncoupling of IL-1 beta and VEGF-A Crosstalk Contributes to Impaired Arteriogenesis Response to Ischemia in Chronic Diabetes Mellitus
IL-1β 和 VEGF-A 串扰的解偶联导致慢性糖尿病缺血的动脉生成反应受损
- 批准号:
10549633 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
The Role of NPR-C In Modulation Of Acute Lung Injury
NPR-C 在调节急性肺损伤中的作用
- 批准号:
9235305 - 财政年份:2015
- 资助金额:
$ 32.49万 - 项目类别:
Uncoupling of IL-1 beta and VEGF-A Crosstalk Contributes to Impaired Arteriogenesis Response to Ischemia in Chronic Diabetes Mellitus
IL-1β 和 VEGF-A 串扰的解偶联导致慢性糖尿病缺血的动脉生成反应受损
- 批准号:
10579818 - 财政年份:2013
- 资助金额:
$ 32.49万 - 项目类别:
相似海外基金
The Role of SECTM1 in Monocyte Biology and Atherosclerosis
SECTM1 在单核细胞生物学和动脉粥样硬化中的作用
- 批准号:
10680450 - 财政年份:2022
- 资助金额:
$ 32.49万 - 项目类别:
The Role of SECTM1 in Monocyte Biology and Atherosclerosis
SECTM1 在单核细胞生物学和动脉粥样硬化中的作用
- 批准号:
10525199 - 财政年份:2022
- 资助金额:
$ 32.49万 - 项目类别:
SPHINGOLIPID BIOLOGY OF MACROPHAGE IN CORONARY ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION
冠状动脉粥样硬化发生和进展中巨噬细胞的鞘脂生物学
- 批准号:
10542823 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
调节 PCSK9 和治疗动脉粥样硬化的化学生物学
- 批准号:
10852687 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
调节 PCSK9 和治疗动脉粥样硬化的化学生物学
- 批准号:
10598882 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
调节 PCSK9 和治疗动脉粥样硬化的化学生物学
- 批准号:
10370428 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
SPHINGOLIPID BIOLOGY OF MACROPHAGE IN CORONARY ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION
冠状动脉粥样硬化发生和进展中巨噬细胞的鞘脂生物学
- 批准号:
10321959 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
调节 PCSK9 和治疗动脉粥样硬化的化学生物学
- 批准号:
10631047 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
调节 PCSK9 和治疗动脉粥样硬化的化学生物学
- 批准号:
10215201 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Role of Shear-Sensitive Protein HEG1 in Endothelial Biology and Atherosclerosis
剪切敏感蛋白 HEG1 在内皮生物学和动脉粥样硬化中的作用
- 批准号:
10459220 - 财政年份:2020
- 资助金额:
$ 32.49万 - 项目类别: